Analysis of prognostic factor in 52 castration-resistant prostate cancer treated with docetaxel
The prognostic factor was retrospectively analyzed in 52 castration-resistant prostate cancer treated with docetaxel (DTX) in our institutions from April, 2006 to August, 2009. The treatment outcomes were decided with prostate specific antigen (PSA) progression-free survival and overall survival. Th...
| Veröffentlicht in: | Hinyokika kiyo. Acta urologica Japonica. - 1962. - 58(2012), 1 vom: 07. Jan., Seite 7-11 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , , , , , , , |
| Format: | Aufsatz |
| Sprache: | Japanese |
| Veröffentlicht: |
2012
|
| Zugriff auf das übergeordnete Werk: | Hinyokika kiyo. Acta urologica Japonica |
| Schlagworte: | Journal Article Antineoplastic Agents Taxoids Docetaxel 15H5577CQD Prostate-Specific Antigen EC 3.4.21.77 |
| Zusammenfassung: | The prognostic factor was retrospectively analyzed in 52 castration-resistant prostate cancer treated with docetaxel (DTX) in our institutions from April, 2006 to August, 2009. The treatment outcomes were decided with prostate specific antigen (PSA) progression-free survival and overall survival. These were calculated by Kaplan-Meier methods and tested with Log-rank test. Median PSA progression-free survival was 8.8 months and median overall survival was 24.1 months. Prognostic factors on PSA progression were PSA value before DTX treatment and rate of PSA decrement after DTX treatment. Prognostic factors on overall survival were Gleason score (GS), PSA value before DTX treatment, rate of PSA decrement after DTX treatment and positive of bone metastasis in Log-rank test. Odds ratio of PSA ≧20 ng/ml before DTX treatment was 2.99 and PSA decreasing rate < 30% was 3.65. These were statistically significant (p < 0.001) risk factors in the overall survival |
|---|---|
| Beschreibung: | Date Completed 10.04.2012 Date Revised 01.12.2018 published: Print Citation Status MEDLINE |
| ISSN: | 0018-1994 |